Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00391872 · ClinicalTrials.gov registry record · Phase 3

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

A Phase 3 study of Acute Coronary Syndrome, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
18,624
Enrollment target
20
Study locations

NCT00391872 is a Phase 3 study of Acute Coronary Syndrome that has completed, run by AstraZeneca. The registered enrollment target is 18,624 participants, above the 2,256-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (726% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00391872, a Phase 3 study of Acute Coronary Syndrome, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
18,624 participants
Enrollment target
20
Study locations

Study Summary

Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.

Conditions Studied

Acute Coronary Syndrome

Interventions

  • DRUG Clopidogrel
  • DRUG Ticagrelor

Study Locations (20)

California

  • Research Site - Bakersfield
  • Research Site - Beverly Hills
  • Research Site - Burbank
  • Research Site - Healdsburg
  • Research Site - Los Angeles
  • Research Site - Roseville
  • Research Site - Sacramento
  • Research Site - San Diego
  • Research Site - Torrance

Alabama

  • Research Site - Birmingham
  • Research Site - Huntsville
  • Research Site - Mobile

Connecticut

  • Research Site - Danbury
  • Research Site - Hartford

Florida

  • Research Site - Atlantis
  • Research Site - Daytona Beach

Arizona

  • Research Site - Tucson

Colorado

  • Research Site - Fort Collins

Delaware

  • Research Site - Newark

District of Columbia

  • Research Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 18,624 participants
Start Date 2006-10
Est. Completion 2009-03
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00391872

The ClinicalTrials.gov registry entry for NCT00391872 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 18,624 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,256-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (726% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.

NCT00391872 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Alabama, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00391872 about?

NCT00391872 is a clinical study titled "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome". Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progre...

What is the current status of trial NCT00391872?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 18,624 participants. The study started on 2006-10. Estimated completion is 2009-03.

What conditions does trial NCT00391872 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT00391872?

The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG).

Who is sponsoring clinical trial NCT00391872?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00391872 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Coronary Syndrome

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.